Shenzhen Edge Medical (HKG:2675) plans to repurchase up to HK$200 million of its shares in the open market under an existing shareholder mandate, according to a Tuesday Hong Kong bourse filing.
The company said repurchases will be conducted from time to time, subject to market conditions.
The buyback authorization may cover up to 10% of the H-shares in issue at the time of the company's Hong Kong listing.
The program will remain in effect until the earlier of the company's next annual general meeting or any shareholder-approved revocation or amendment of the mandate.